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Human parvovirus B19 (B19) is a common infec-
tious pathogen in humans [1]. Since its discovery,
B19 has been linked with a broad spectrum of
clinical syndromes. An aetiological role of the
virus has been conﬁrmed in erythema infection,
transient aplastic crisis, persistent infection man-
ifesting as pure red cell aplasia in immunocom-
promised persons, non-immune hydrops fetalis
and arthritis. Less commonly recognized, but
receiving increasing attention, are the neurolog-
ical manifestations, a variety of which have been
described in patients with either clinically
diagnosed or laboratory-conﬁrmed B19 infection
[2].
Meningoencephalitis due to B19 in adults is a
rare entity and, to our knowledge, only several
cases have been reported in the literature [3–7]
(Table 1). We describe here a case of aseptic
meningoencephalitis caused by B19 in an immu-
nocompetent patient who had predominating
psychiatric symptoms.
A 75-year-old, previously healthy retired doc-
tor was admitted to hospital because of abrupt
onset of headache, confusion, agitation, dysar-
thria and fever. Physical examination revealed
apparent neck stiffness. The initial fever was
c. 38C and resolved in 2 days. Psychiatric exam-
ination revealed confusion, irritability, agitation,
disorientation, language disturbance, difﬁculty in
object naming, mood swings, persecutory delu-
sions and delusions of inﬂuence, tactile and visual
hallucinations and increasedpsychomotor activity.
The patient displayed sudden impairment of
attention-focus, perception and cognition, and
disturbance of consciousness. These may have
resulted from the direct invasion of the central
nervous system by B19 or from indirect effects of
the immune response to the infection.
Routine laboratory ﬁndings (biochemistry, clin-
ical haematology and urine analysis) were nor-
mal. The values for peripheral blood leukocytes,
erythrocyte sedimentation rate and C-reactive
protein level were normal. Analysis of cerebro-
spinal ﬂuid (CSF) obtained by lumbar puncture at
high opening pressure showed a xanthochromic
appearance, an elevated white blood cell count
(210 ⁄mm3) with a predominance of lymphocytes
(95%), and increased total protein (242 mg ⁄dL)
and glucose levels (74 mg ⁄dL; simultaneous
blood glucose level, 120 mg ⁄dL). Microbiological
assays and repeated cultures of blood and CSF
did not reveal any bacterial, fungal or parasitic
infection. Tuberculosis was ruled out on the basis
of negative PCR results and the repeated absence
of Mycobacterium tuberculosis, after Ziehl–Nielsen
staining and 8 weeks of culture on Lo¨wenstein–
Jensen medium.
Magnetic resonance imaging did not show any
cerebral or cerebellar abnormalities, apart from
Table 1. Clinical and laboratory characteristics of documented cases of adult meningoencephalitis associated with
infection due to parvovirus B19
Reference Age (years) ⁄ sex
B19-related symptoms
Sequela ⁄death
B19 markers in serum B19 markers in CSF
Rash Anaemia Arthralgia IgM IgG DNA IgM IgG DNA
[3] 35 ⁄M ) + ) ) ⁄) + + + ND ND +
[4] 26 ⁄ F ) + ) ) ⁄+ + + + ND ND +
[5] 17 ⁄ F ) ) ) ) ⁄) + + ) ND ND +
[6] 67 ⁄ F ) + ) ) ⁄) ) + ) ) + +
[7] 58 ⁄ F ) ) ) ) ⁄+ + + ) ) + +
PR 75 ⁄M ) ) ) ) ⁄) ) + ) ) ) +a
CSF, cerebrospinal ﬂuid; PR, present report; M male; F, female; ND, not done.
a103 copies ⁄mL.
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minimal cortical atrophy and gliosis. Electroen-
cephalography showed generalized slow (theta)-
wave activity, which is a non-speciﬁc ﬁnding.
Virological assays of blood and CSF were not
indicative of human immunodeﬁciency virus,
herpes simplex virus, cytomegalovirus, Epstein–
Barr virus or mumps virus.
The clinical condition continued to deteriorate
under empirical therapy including broad-spec-
trum antibiotic and antiviral therapy (ceftriaxone
2 · 2 g ⁄day, acyclovir 10 mg ⁄kg, intravenous,
three times daily). B19 DNA was detected twice
in the patient’s CSF using PCR, after 6 and
20 days of hospitalization. Although tests for
anti-B19 IgM and IgG in the CSF were negative,
it was positive for IgG in the serum at the sixth
day. The clinical manifestations persisted for
about 3 weeks with a continuous pattern. The
physical symptoms, including mental and cogni-
tive functions and dysarthria, abated completely
at the end of 1 month.
The TaqMan real-time PCR assay was per-
formed by using the CHROMO4 Real-time PCR
Detector (BioRad, Hercules, CA, USA). PCR
products were digested with BsaI in order to
check for speciﬁcity. In this study, when B19 PCR
products were digested with BsaI, two fragments
of 54 and 68 bp were detected, as expected. A
commercial ELISA test (recomWell Parvovirus
B19 Ig; Mikrogen, Neuried, Germany) was
performed for the detection of IgG and IgM
according to the manufacturer’s instructions.
Infection with B19 has been associated with
various neurological manifestations, including
encephalitis, seizures, disturbance of conscious-
ness, meningitis, cerebellar ataxia, transverse
myelitis, optic neuropathy, neurological amyo-
trophy, Guillain–Barre´ syndrome, paraesthesia
and carpal tunnel syndrome [2]. In two retrospec-
tive studies, B19 virus was detected in 4.6% and
4.3% of undiagnosed cases of meningoencepha-
litis [8,9].
Patients with viral meningoencephalitis usually
have signs and symptoms of meningeal inﬂam-
mation, but, in addition to headache, fever and
nuchal rigidity, viral meningoencephalitis is char-
acterized by alterations of consciousness [10]. Our
patient was diagnosed as having B19 meningoen-
cephalitis with the inﬂammatory central nervous
system (CNS) proﬁle, abnormal mental activity,
cognitive disorders, dysarthria and apparent neck
stiffness in conjunction with the negative micro-
biological data. Generally, the neuropsychiatric
changes are seen in childhood B19 meningoen-
cephalitis [1,2,9]. To the authors’ knowledge, the
present case differs from other adult cases
reported in the literature, due to the dominant
pattern of symptoms including cerebral involve-
ment with cognitive disorders, personality
changes and dysarthria. Moreover, the level of
B19 DNA was relatively low in CSF and the virus
was absent in serum, which might be indicative of
a subacute or chronic infection.
A Medline search of the literature for adult
meningoencephalitis due to B19 revealed only
ﬁve cases [3–7]. In these cases, the predominant
clinical manifestations of CNS involvement were
as follows: the typical maculopapular rash
occurred only in one case [5]; arthralgia was not
seen in any case, and anaemia was observed in
three cases [3,4,6]; in one case, no typical
B19-related symptoms were observed, but
prolonged fever was present for 20 days [5]; and
two of the ﬁve patients died [4,7].
There is one report of administration of intra-
venous immunoglobulin (IVIG) to two patients
with presumed chronic B19 infection and chronic
arthritis [11]. Aggressive therapy with IVIG is
generally limited to patients with chronic B19
infection and chronic anaemia [12]. In only one
reported case was a patient with CNS involve-
ment given IVIG, after which the infection sub-
sided [2]. However, comprehensive data
concerning CNS infections are lacking.
The patient of this study represents a rare case
of B19 infection associated with neuropsychiatric
disorders, and B19 might be the responsible agent
for CNS infections particularly in those without
speciﬁc diagnosis.
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Trichoderma fungaemia in a neutropenic
patient with pulmonary cancer and human
immunodeﬁciency virus infection
10.1111/j.1469-0691.2008.02111.x
A 58-year-old man who has been infected with
human immunodeﬁciency virus (HIV) since
1986 presented with fully suppressed plasma
HIV replication while undergoing combination
antiretroviral therapy, and with a persistent
cellular immune deﬁciency (CD4 cell count =
212 ⁄mm3). In 2005, he had been diagnosed
with bronchopulmonary adenocarcinoma
(T2N0M0), and a lobectomy was undertaken
and adjunctive chemotherapy was given. At ﬁrst
tumour relapse in 2006, he was treated with
three cycles of chemotherapy and radiotherapy.
In March 2007, a second relapse was diagnosed,
and treatment with carboplatine, vinorelbine
and steroids (solumedrol 120 mg at day 1 and
oral methylprednisolone 40 mg at day 2) was
initiated on 13 April. After the ﬁrst treatment
cycle, the patient presented with a febrile
aplasia, and co-amoxiclav and oﬂoxacin were
prescribed. A second chemotherapy cycle was
completed on 22 May, and on 25 May, the
patient presented with a 1-day history of fever,
chills and abdominal pain. Upon admission, his
temperature was 38.5C, his heart rate was
130 beats ⁄min and his blood pressure was
130 ⁄ 80 mmHg. Clinical examination revealed a
generalized abdominal tenderness and diar-
rhoea, as well as severe leukopenia (leukocyte
count, 300 ⁄mm3; neutrophil count not per-
formed) and anaemia. Urine culture remained
sterile. Chest X-ray showed no inﬁltrate. Treat-
ment with broad-spectrum antibiotics was initi-
ated (piperacillin–tazobactam and amikacin).
Blood cultures obtained from both the central
venous catheter (a long-duration chamber cath-
eter had been in place since 2006) and a
peripheral vein upon admission yielded wild-
type Escherichia coli, suggesting intestinal trans-
location. On day 5 after admission (30 May)
the neutrophil count rose above 500 ⁄mm3, and
treatment with piperacillin–tazobactam was
replaced by treatment with amoxycillin for a
total duration of 9 days. One blood culture
(using BacT ⁄Alert; BioMe´rieux, Lyon, France)
of a sample drawn at admission (25 May) from
a peripheral vein yielded a mould identiﬁed as
Trichoderma longibrachiatum.
Identiﬁcation was conﬁrmed by DNA
ampliﬁcation and sequencing of a fragment,
including the 3¢-end of the 18S rRNA gene,
internal transcribed spacer (ITS)-1, the 5.8S rRNA
gene, ITS-2, and the 5¢-end of the 28S rRNA gene
(ITS-1–ITS-2) (National Reference Centre for
Mycoses, Institut Pasteur, Paris).
The same mould was isolated from two addi-
tional blood cultures (three positive blood cul-
tures in total) drawn from the central venous
catheter on 28 and 31 May, whereas the matching
blood cultures drawn from peripheral veins
remained negative. Intravenous antifungal ther-
apy was initiated with amphotericin B
(1 mg ⁄ kg ⁄day) on 31 May, and the central venous
catheter was removed on 1 June.
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